Presentation
Cardio-oncology, a burgeoning field in clinical cardiology, recognises the heightened risk of cardiovascular disease (CVD) among cancer survivors, necessitating dedicated cardio-oncology services. Timely diagnosis of CVD in these patients remains a major challenge, highlighting the need for accessible and cost-effective diagnostic tools, such as biomarkers.
While cardiac troponins and natriuretic peptides have emerged as powerful diagnostic and prognostic tools in various CVDs, their utility in cardio-oncology settings warrants further investigation. Additionally, emerging biomarkers hold promise in providing insights into cardiovascular and cancer-related events affecting the cardiovascular system.
Our Study Group endeavours to organise webinars and workshops to explore the role of biomarkers, foster discussions among colleagues, and advance knowledge and treatment in cardio-oncology.
These revisions aim to enhance the consistency and coherence across the manuscript sections while ensuring clarity and precision in conveying the respective messages of each Study Group.
